Skip to content

CASSIPHARMA

Active Private limited company (pre-2019)founded 2002active for 24 yearsKoning Boudewijnstraat 25, 9000 GhentKBO/BCE: BE 0477.736.777 subsidiary of

Board

1 director, no change since 2023
Director (not named in the articles), permanent representative
appointed by deed of 20-02-2023 term without a fixed end
earlier manager, until 20-02-2023
also on the board of 1 other company
listed in the 2025 annual accounts, filed on 30-01-2026
Signing authorityThe articles say who may bind the company, for example by signing a contract.
Each director alone
deed of 20-02-2023
Permanent representatives 1
Permanent representative, for
appointed by deed of 20-02-2023

Office holders in the KBO →

Mandates through the years

2 names, the dashed line is today

Director (not named in the articles)

Statutory manager
BoardEarliermandate already running before its first mention
Mandates as a list
    • Manager (not named in the articles), appointed by deed of 17-02-2014, until 20-02-2023
    • Director (not named in the articles), appointed by deed of 20-02-2023, still in office
    • Statutory manager, until 17-02-2014

Control

Parent
Equity €2.8m
Profit €91,699 in 2025 (profit €136,259 in 2024)
Source: accounts 30-06-2025
99%
This company
CASSIPHARMA
Equity €217,796
Profit €8,177 in 2025

Capital

Contribution
€7,844.54
Shares
100
Contribution per share
€78.45
Equity per share
€2,178 in 2025
Source
2025 annual accounts

Owners through the years

as the annual accounts name them
99%
Owners as a list
    • 2015 to 2025: 99%

Source: lists of holdings in the owners' accounts

Articles of association

deed of 20-02-2023 (in Dutch)
DurationMost companies exist for an unlimited period, until they are dissolved.
Unlimited
Annual meetingThe shareholders approve the annual accounts, among other things, at the annual meeting.
Last Friday of December

Capital transactions

Capital over time
  1. 20-02-2023 Converted to available equity
  2. 14-12-2022 Capital stated in the deed · €18,600 · 100 shares

Next steps